Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea
PERTH, Australia, May 17, 2011 /PRNewswire/ -- Australian supplier of API analytical standards Epichem, announced today it has signed an exclusive distributor agreement with a leading Japanese Life Sciences supplier company, AR Brown, for sales to Japan, Taiwan, China and South Korea.
Headquartered in Tokyo, AR Brown is one of Japan's largest distributors in the chemical, pharmaceutical and biotechnology industries and have earned the reputation as a strong and reliable supplier. They manage a large and sophisticated network of supplier partnerships in several countries. The strong business relationships established over 50 years allow AR Brown to provide technical knowledge and information needed to their large customer base to actively sell Epichem's API analytical standards primarily to support the various needs of companies manufacturing over-the-counter and generic medicines.
Dr Wayne Best, Managing Director of Epichem commented, "Epichem is globally competitive with clients in over 20 countries and is rapidly expanding its reach. I am very proud that Epichem has joined forces with AR Brown to open these new markets. AR Brown has a long and successful trading history and is highly respected in the region. It is satisfying to find a distributor whose motto is "Think Quality". This motto emulates the culture at Epichem and prevails right through our range of products and services. AR Brown is exactly the kind of distributor we were looking for in this region. We are currently seeking distribution in Europe, South America, the United States and Canada."
Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Perth, Australia, Epichem has been delivering synthetic and medicinal chemistry services to the drug discovery and pharmaceutical industries for more than 7 years. Epichem offers a range of rare and hard to find pharmaceutical impurities, degradants and metabolites of active ingredients and excipients, particularly for OTC and generic drugs. Epichem has been at the forefront of synthesizing new and difficult to obtain standards and many of these are exclusive to Epichem and not available elsewhere. This range is continually expanding in response to customer requests and developments in the industry. The company has a robust Quality System in place and all batches of standards are fully traceable. Epichem's laboratory and systems have passed audits by four of the world's top pharmaceutical companies and all standards are supplied with a Certificate of Analysis and MSDS. These standards can be supplied in multigram quantities which is ideal for companies undertaking rapid and cost effect stability testing for product development. Epichem maintains stocks of its standards and can thus be shipped to customers immediately. Epichem also excels in custom synthesis and contract drug discovery, boasting a highly skilled team of scientists, most with a PhD and industry experience. This valuable investment in people allows Epichem to lead drug discovery programs, perform custom synthesis, conduct optimisation and method development for scale-up and engage in high-level problem solving.
Epichem Pty Ltd, Murdoch University Campus, South Street, Murdoch WA 6150, AustraliaTel + 61 (0)8 9360 7696Fax + 61 (0)8 9360 7699www.epichem.com.auABN 80 106 769 902
For more information:Barry EpsteinVice President MarketingTelephone +61 (0)8 9360 7696Mobile/Cell + 61 (0)488 236 600Email email@example.com Website www.epichem.com.au
Toshinori FujiwaraProduct Manager, Life SciencesTelephone +81 6 6282 4004Mobile/Cell +81 (90) 2164-3121Email firstname.lastname@example.org Website www.arbrown.com
SOURCE Epichem Pty Ltd